Quick Answer
AC Immune SA reported R&D Expense of $56.44 million for fiscal year 2025.
AC Immune SA R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $56.44M | -9.8% |
| 2024 | $62.57M | +14.6% |
| 2023 | $54.61M | -9.5% |
| 2022 | $60.34M | -3.1% |
| 2021 | $62.28M | +4.7% |
| 2020 | $59.49M | +18.0% |
| 2019 | $50.43M | +13.9% |
| 2018 | $44.28M | +35.6% |
| 2017 | $32.66M | +26.7% |
| 2016 | $25.77M | +51.2% |
| 2015 | $17.05M | — |
- AC Immune SA showed a decrease of -9.8% in R&D Expense compared to the prior fiscal year.
- Over the 2015–2025 period, AC Immune SA’s r&d expense has grown by 231.0% (from $17.05 million to $56.44 million).
- The most recent figure is from AC Immune SA’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: